Chat with us, powered by LiveChat

Loading...

Antinuclear Antibody Testing Market Report

RA08330

Antinuclear Antibody Testing Market, by Product (Reagents & Assay Kits, Systems And Software & Services), Technique (ELISA, Immunofluorescence Assay And Multiplex Assay), Application (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren’s Syndrome, Scleroderma And Others), End Use (Hospitals, Clinical Laboratories, Physician Office Laboratories And Others), Regional Outlook (North America, Europe, Asia-Pacific, And LAMEA): Global Opportunity Analysis And Industry Forecast, 2019–2027

RA08330

Pages: 247

Nov 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Antinuclear Antibody Testing Market

Antinuclear antibody testing market accounted for $1,080.1 million in 2019 and is predicted to generate a revenue of $ 2,766.5 million by 2027 with a CAGR of 13.0% in the estimated period. Asia-Pacific region market accounted for $211.1 million in 2019 and is predicted to grow with a CAGR of 15.3% in the estimated period.

Market Analysis

Antinuclear antibody testing is used for finding antinuclear antibodies present the body. If the test results are positive, then there are high chances that the person might have autoimmune disorders. Autoimmune disorder is when the immune system mistakenly attacks its own cells, tissues, or organs. This disorder can cause serious health issues.

COIVD Analysis of the Antinuclear Antibody Testing Market

The pandemic is predicted to have a significant positive impact on the global antinuclear antibody testing market. As a result of the novel coronavirus outbreak, most industrial sites are shut down and many companies have adopted work from home option but the health care institutions have taken multiple steps and are working actively for the development of various vaccines and treating people. The antinuclear antibody test market is predicted to grow enormously, and the growth is majorly due to increase in the number of people taking antinuclear antibody tests to evaluate autoimmune disorders during the pandemic to keep a tab on one’s health. This factor is directly impacting the demand for antinuclear antibody test and is predicted to fuel the growth of the market in the emergency time.

Increasing cases of autoimmune diseases across the globe is predicted to be the major driving factor for the global market

Autoimmune diseases are a serious health threat, which may cause systemic lupus erythematosus, rheumatoid arthritis, scleroderma, and Sjogren's syndrome. Antinuclear antibody test is used to find the antinuclear antibodies in a person’s blood serum. For instance, in Nov 2019, according to America Autoimmune Related Diseases Association (AARDA), autoimmune diseases had affected about 20% of U.S. population with 75% being women. Rising cases of autoimmune disease increase the demand for ANA tests among end users. Increasing cases of autoimmune diseases is predicted to be the major driving factor for the global antinuclear autoimmune test market in the estimated period. In addition, majority of people are covered under medical insurance due to government initiatives to create awareness about benefits of medical insurance, which is expected to boost the growth of the antinuclear antibody market in the estimated period.

Government rules and regulation for approval of various medical equipment is predicted to be a major restraint for the antinuclear antibody testing market

Safety can only be considered in relative terms. All devices carry a certain degree of risk and could cause problems in specific circumstances. Stringent regulations on the approval and adoption of antinuclear antibody medical devices due to increasing concerns over consistency of testing devices is predicted to hamper the growth of the antinuclear antibody market in the forecast years. For instance, according to global harmonization task force, countries need to ensure that their regulatory controls should be in significant conflict with global health management institution. Recommendations of safety and performance requirements, quality systems, standards and procedures of post-market surveillance are studied in-depth by experts from different countries to reach consensual recommendations. In addition, huge investments are required for setting up and installing the test devices which is predicted to be the biggest restraint for the market in the estimated period.

Rising investment in developing test kits is predicted to create more growth opportunity for the market in the estimated period

Increasing investments for the automation of medical laboratories especially in the developing countries, due to rising investments for healthcare infrastructure and test kits, is estimated to generate ample growth opportunities for the antinuclear antibody market in the estimated timeframe.

Antinuclear Antibody Testing Market, By Product

Reagents & assay kits sub-segment is predicted to be the most lucrative

Antinuclear Antibody Testing Market, By Product

Source: Research Dive Analysis

Reagents & assay kits sub-segment is predicted to have the maximum market share in the forecast period. Reagents & assay kits sub-segment accounted for $642.1 million in 2019 and is predicted to grow with a CAGR of 13.6% in the estimated period. Rise in the use of these kits for various research and development purposes for better understanding of various type of diseases is predicted to be the major driving factor for the sub-segment market in the estimate period.

Antinuclear Antibody Testing Market, By Technique:

ELISA technique is predicted to have the highest market share

Antinuclear Antibody Testing Market, By Technique

Source: Research Dive Analysis

ELISA sub-segment is predicted to grow enormously in terms of revenue in the estimated period. ELISA sub-segment accounted for $430.5 million in 2019 and is predicted to grow with a CAGR of 13.7% in the estimated period. ELISA is a rapid test that displays results at a faster rate in comparison to other testing techniques which is predicted to be a major boost to the sub-segment market in the estimated period.

Antinuclear Antibody Testing Market, By Application:

The highest market share in application segment will be rheumatoid arthritis by 2027

Antinuclear Antibody Testing Market, By Application

Source: Research Dive Analysis

Rheumatoid arthritis sub-segment is predicted to hold the highest share as well as maximum revenue in the estimated period. Rheumatoid arthritis sub-segment accounted for $752.3 million in 2019 and is predicted to grow with a CAGR of 13.5% in the estimated period. Rise in the geriatric population across the globe and rise in the occurrences of rheumatoid arthritis is predicted to be the major driving factor for the rheumatoid arthritis sub-segment market in the estimated period.

Antinuclear Antibody Testing Market, End Use:

Hospital end use sub segment is predicted to hold maximum market share

Antinuclear Antibody Testing Market, End Use

Source: Research Dive Analysis

Hospital sub-segment is predicted to hold the highest share in the forecast period. Hospital sub-segment accounted for $452.3 million in 2019 and is predicted to grow with a CAGR of 12.5% in the projected timeframe. Rise in patient satisfaction, outpatient services and increased home care facilities provided by the hospital is predicted to drive the hospital sub segment market in the estimated period.

Antinuclear Antibody Testing Market, By Region:

North America region market is predicted to create more growth opportunity for the global market in the forecast period

Antinuclear Antibody Testing Market, By Region

Source: Research Dive Analysis

North America region market is predicted to have highest market share in the estimated period. North America region market accounted for $392.3 million in 2019 and is predicted to grow with a CAGR of 11.9% in the estimated period. The growing incidence of autoimmune diseases across the region will help in driving the growth of the anti-nuclear antibody test market. In addition, with rise in population, the chances of prevalence of autoimmune disease will increase simultaneously which is predicted to boost the region market in the estimated period. For instance, it has been estimated by UN that only in U.S, the population may rise up to 359.4 million by the end of 2025.

Key Participants in The Antinuclear Antibody Testing Market:

Key Participants in The Antinuclear Antibody Testing Market

Source: Research Dive Analysis

Some of the significant antinuclear antibody testing market players include Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc. There are various strategies which the companies are adopting for expanding business and creating more growth opportunity. For instance, In Aug 2019 ERBA Mannheim promised to deliver unrivalled affordability and technology in a burst of new product launches at this year’s AACC. The company is planning for new product launches across Hematology, Clinical Chemistry and Immunology specialties.

Porter’s Five Forces Analysis for Antinuclear Antibody Testing Market:

  • Bargaining Power of Suppliers: There are not many suppliers in the market. The bargaining power of suppliers is Moderate.
  • Bargaining Power of Consumers: In this market, the concentration of buyers is Medium. The bargaining power of consumers is Moderate.
  • Threat of New Entrants: Huge initial investments are essential to start a new manufacturing unit of ozone generator. The threat of new entrants is High.
  • Threat of Substitutes: This market has less products due to which switching costs for clients is moderate. The threat of substitutes is Medium.
  • Competitive Rivalry in the Market: The ANA test market has numerous small, medium and large, scale players. The competitive rivalry in the industry is Moderate.
     

Aspect

Particulars

  Historical Market Estimations

  2019-2020

  Base Year for Market Estimation

  2019

  Forecast timeline for Market Projection

  2020-2027

  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Product

  • Reagents & Assay Kits
  • Systems
  • Software & Services

  Segmentation by Technique

  • ELISA
  • Immunofluorescence Assay
  • Multiplex Assay

  Segmentation by Application

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Sjogren’s Syndrome
  • Scleroderma
  • Others

  Segmentation by End Use

  • Hospitals
  • Clinical Laboratories
  • Physician Office Laboratories
  • Others

  Key Countries Covered

U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, South Korea, Rest of Asia-Pacific, Latin America, Middle East, Africa

  Key Companies Profiled

  • Erba Diagnostics

  • Bio-Rad Laboratories, Inc.

  • Trinity Biotech Plc.

  • Thermo Fisher Scientific

  • Antibodies Incorporated

  • EUROIMMUN Medizinische Labordiagnostika AG

  • Immuno Concepts NA Ltd.

  • Inova Diagnostics, Inc.

  • ZEUS Scientific, Inc.


Frequently Asked Questions
 

A. The global antinuclear antibody testing market size was over $1,080.1 million in 2019, and is predicted to grow with a CAGR of 13.0% over the forecast period.

A. Erba Diagnostics and Bio-Rad Laboratories, Inc. are some of the key players in the global antinuclear antibody testing market.

A. North America possesses great investment opportunities for the investors to witness the most promising growth in the coming years.

A. North America antinuclear antibody testing market is projected to grow at 11.9% CAGR during the forecast period.

A. Product development is the key strategies opted by the operating companies in this antinuclear antibody testing market.

A. Erba Diagnostics is the company investing more on R&D activities for developing new products and technologies.

1. Research Methodology

1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters

1.4.1. Assumptions
1.4.2. Forecast parameters

1.5. Data sources

1.5.1. Primary
1.5.2. Secondary

2. Executive Summary

2.1. 360° summary
2.2. Product trends
2.3. Technique trends
2.4. Application trends
2.5. End use trends

3. Market overview

3.1. Market segmentation & definitions
3.2. Key takeaways

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of consumers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of new entrants
3.3.4. Threat of substitutes
3.3.5. Competitive rivalry in the market

3.4. Market dynamics

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities

3.5. Technology landscape
3.6. Regulatory landscape
3.7. Patent landscape
3.8. Pricing overview

3.8.1. By Product
3.8.2. By Techniques
3.8.3. By Application 
3.8.4. By End use
3.8.5. By region

3.9. Market value chain analysis

3.9.1. Stress point analysis
3.9.2. Raw material analysis
3.9.3. Manufacturing process
3.9.4. Distribution channel analysis
3.9.5. Operating vendors

3.9.5.1. Raw material suppliers
3.9.5.2. Product manufacturers
3.9.5.3. Product distributors

3.10. Strategic overview

4. Antinuclear Antibody Test Market , by Product

4.1. Reagents & Assay Kits

4.1.1. Market size and forecast, by region, 2019-2027
4.1.2. Comparative market share analysis, 2019-2027

4.2. Systems

4.2.1. Market size and forecast, by region, 2019-2027
4.2.2. Comparative market share analysis, 2019-2027

4.3. Software & Services

4.3.1. Market size and forecast, by region, 2019-2027
4.3.2. Comparative market share analysis, 2019-2027

5. Antinuclear Antibody Test Market , by Technique

5.1. ELISA

5.1.1. Market size and forecast, by region, 2019-2027
5.1.2. Comparative market share analysis, 2019-2027

5.2. Immunofluorescence Assay

5.2.1. Market size and forecast, by region, 2019-2027
5.2.2. Comparative market share analysis, 2019-2027

5.3. Multiplex Assay

5.3.1. Market size and forecast, by region, 2019-2027
5.3.2. Comparative market share analysis, 2019-2027

6. Antinuclear Antibody Test Market , by Application

6.1. Rheumatoid Arthritis

6.1.1. Market size and forecast, by region, 2019-2027
6.1.2. Comparative market share analysis, 2019-2027

6.2. Systemic Lupus Erythematosus

6.2.1. Market size and forecast, by region, 2019-2027
6.2.2. Comparative market share analysis, 2019-2027

6.3. Municipal

6.3.1. Market size and forecast, by region, 2019-2027
6.3.2. Comparative market share analysis, 2019-2027

6.4. Sjogren’s Syndrome 

6.4.1. Market size and forecast, by region, 2019-2027
6.4.2. Comparative market share analysis, 2019-2027

6.5. Scleroderma

6.5.1. Market size and forecast, by region, 2019-2027
6.5.2. Comparative market share analysis, 2019-2027

6.6. Others

6.6.1. Market size and forecast, by region, 2019-2027
6.6.2. Comparative market share analysis, 2019-2027

7. Antinuclear Antibody Test Market , by Technique

7.1. Hospitals

7.1.1. Market size and forecast, by region, 2019-2027
7.1.2. Comparative market share analysis, 2019-2027

7.2. Clinical Laboratories

7.2.1. Market size and forecast, by region, 2019-2027
7.2.2. Comparative market share analysis, 2019-2027

7.3. Physician Office Laboratories

7.3.1. Market size and forecast, by region, 2019-2027
7.3.2. Comparative market share analysis, 2019-2027

7.4. Others

7.4.1. Market size and forecast, by region, 2019-2027
7.4.2. Comparative market share analysis, 2019-2027

8. Disaster Recovery as Antinuclear Antibody Test Market , by Region

8.1. North Region

8.1.1. Market size and forecast, by Product, 2019-2027
8.1.2. Market size and forecast, by Technique, 2019-2027
8.1.3. Market size and forecast, by Application, 2019-2027
8.1.4. Market size and forecast, by End Use, 2019-2027
8.1.5. Market size and forecast, by country, 2019-2027
8.1.6. Comparative market share analysis, 2019-2027
8.1.7. U.S
8.1.8. Market size and forecast, by Product, 2019-2027
8.1.9. Market size and forecast, by Technique, 2019-2027
8.1.10. Market size and forecast, by Application, 2019-2027
8.1.11. Market size and forecast, by End Use, 2019-2027
8.1.12. Market size and forecast, by vertical, 2019-2027
8.1.13. Canada
8.1.14. Market size and forecast, by Product, 2019-2027
8.1.15. Market size and forecast, by Technique, 2019-2027
8.1.16. Market size and forecast, by Application, 2019-2027
8.1.17. Market size and forecast, by End Use, 2019-2027

8.2. Europe

8.2.1. Market size and forecast, by Product, 2019-2027
8.2.2. Market size and forecast, by Technique, 2019-2027
8.2.3. Market size and forecast, by Application, 2019-2027
8.2.4. Market size and forecast, by End Use, 2019-2027
8.2.5. Market size and forecast, by country, 2019-2027
8.2.6. Comparative market share analysis, 2019-2027
8.2.7. UK

8.2.7.1. Market size and forecast, by Product, 2019-2027
8.2.7.2. Market size and forecast, by Technique, 2019-2027
8.2.7.3. Market size and forecast, by Application, 2019-2027
8.2.7.4. Market size and forecast, by End Use, 2019-2027
8.2.7.5. Comparative market share analysis, 2019-2027

8.2.8. Germany

8.2.8.1. Market size and forecast, by Product, 2019-2027
8.2.8.2. Market size and forecast, by Technique, 2019-2027
8.2.8.3. Market size and forecast, by Application, 2019-2027
8.2.8.4. Market size and forecast, by End Use, 2019-2027
8.2.8.5. Comparative market share analysis, 2019-2027

8.2.9. France

8.2.9.1. Market size and forecast, by Product, 2019-2027
8.2.9.2. Market size and forecast, by Technique, 2019-2027
8.2.9.3. Market size and forecast, by Application, 2019-2027
8.2.9.4. Market size and forecast, by End Use, 2019-2027
8.2.9.5. Comparative market share analysis, 2019-2027

8.2.10. Italy

8.2.10.1. Market size and forecast, by Product, 2019-2027
8.2.10.2. Market size and forecast, by Technique, 2019-2027
8.2.10.3. Market size and forecast, by Application, 2019-2027
8.2.10.4. Market size and forecast, by End Use, 2019-2027
8.2.10.5. Comparative market share analysis, 2019-2027

8.2.11. Rest of Europe

8.2.11.1. Market size and forecast, by Product, 2019-2027
8.2.11.2. Market size and forecast, by Technique, 2019-2027
8.2.11.3. Market size and forecast, by Application, 2019-2027
8.2.11.4. Market size and forecast, by End Use, 2019-2027
8.2.11.5. Comparative market share analysis, 2019-2027

8.3. Asia-Pacific

8.3.1. Market size and forecast, by Product, 2019-2027
8.3.2. Market size and forecast, by Technique, 2019-2027
8.3.3. Market size and forecast, by Application, 2019-2027
8.3.4. Market size and forecast, by End Use, 2019-2027
8.3.5. Comparative market share analysis, 2019-2027
8.3.6. Market size and forecast, by country, 2019-2027
8.3.7. China

8.3.7.1. Market size and forecast, by Product, 2019-2027
8.3.7.2. Market size and forecast, by Technique, 2019-2027
8.3.7.3. Market size and forecast, by Application, 2019-2027
8.3.7.4. Market size and forecast, by End Use, 2019-2027
8.3.7.5. Comparative market share analysis, 2019-2027

8.3.8. India

8.3.8.1. Market size and forecast, by Product, 2019-2027
8.3.8.2. Market size and forecast, by Technique, 2019-2027
8.3.8.3. Market size and forecast, by Application, 2019-2027
8.3.8.4. Market size and forecast, by End Use, 2019-2027
8.3.8.5. Comparative market share analysis, 2019-2027

8.3.9. Japan

8.3.9.1. Market size and forecast, by Product, 2019-2027
8.3.9.2. Market size and forecast, by Technique, 2019-2027
8.3.9.3. Market size and forecast, by Application, 2019-2027
8.3.9.4. Market size and forecast, by End Use, 2019-2027
8.3.9.5. Comparative market share analysis, 2019-2027

8.3.10. South Korea

8.3.10.1. Market size and forecast, by Product, 2019-2027
8.3.10.2. Market size and forecast, by Technique, 2019-2027
8.3.10.3. Market size and forecast, by Application, 2019-2027
8.3.10.4. Market size and forecast, by End Use, 2019-2027
8.3.10.5. Comparative market share analysis, 2019-2027

8.3.11. Australia

8.3.11.1. Market size and forecast, by Product, 2019-2027
8.3.11.2. Market size and forecast, by Technique, 2019-2027
8.3.11.3. Market size and forecast, by Application, 2019-2027
8.3.11.4. Market size and forecast, by End Use, 2019-2027
8.3.11.5. Comparative market share analysis, 2019-2027

8.3.12. Rest of Asia Pacific

8.3.12.1. Market size and forecast, by Product, 2019-2027
8.3.12.2. Market size and forecast, by Technique, 2019-2027
8.3.12.3. Market size and forecast, by Application, 2019-2027
8.3.12.4. Market size and forecast, by End Use, 2019-2027
8.3.12.5. Comparative market share analysis, 2019-2027

8.4. LAMEA

8.4.1.1. Market size and forecast, by Product, 2019-2027
8.4.1.2. Market size and forecast, by Technique, 2019-2027
8.4.1.3. Market size and forecast, by Application, 2019-2027
8.4.1.4. Market size and forecast, by End Use, 2019-2027
8.4.1.5. Market size and forecast, by country, 2019-2027
8.4.1.6. Comparative market share analysis, 2019-2027

8.4.2. Latin America

8.4.2.1. Market size and forecast, by Product, 2019-2027
8.4.2.2. Market size and forecast, by Technique, 2019-2027
8.4.2.3. Market size and forecast, by Application, 2019-2027
8.4.2.4. Market size and forecast, by End Use, 2019-2027
8.4.2.5. Comparative market share analysis, 2019-2027

8.4.3. Middle East

8.4.3.1. Market size and forecast, by Product, 2019-2027
8.4.3.2. Market size and forecast, by Technique, 2019-2027
8.4.3.3. Market size and forecast, by Application, 2019-2027
8.4.3.4. Market size and forecast, by End Use, 2019-2027
8.4.3.5. Comparative market share analysis, 2019-2027

8.4.4. Africa

8.4.4.1. Market size and forecast, by Product, 2019-2027
8.4.4.2. Market size and forecast, by Technique, 2019-2027
8.4.4.3. Market size and forecast, by Application, 2019-2027
8.4.4.4. Market size and forecast, by End Use, 2019-2027
8.4.4.5. Comparative market share analysis, 2019-2027

9. Company profiles

9.1. Erba Diagnostics

9.1.1. Business overview
9.1.2. Financial performance
9.1.3. Product portfolio
9.1.4. Recent strategic moves & developments
9.1.5. SWOT analysis

9.2. Bio-Rad Laboratories, Inc.,

9.2.1. Business overview
9.2.2. Financial performance
9.2.3. Product portfolio
9.2.4. Recent strategic moves & developments
9.2.5. SWOT analysis

9.3. Trinity Biotech Plc

9.3.1. Business overview
9.3.2. Financial performance
9.3.3. Product portfolio
9.3.4. Recent strategic moves & developments
9.3.5. SWOT analysis

9.4. Dayton Water Systems

9.4.1. Business overview
9.4.2. Financial performance
9.4.3. Product portfolio
9.4.4. Recent strategic moves & developments
9.4.5. SWOT analysis

9.5. Thermo Fisher Scientific.,

9.5.1. Business overview
9.5.2. Financial performance
9.5.3. Product portfolio
9.5.4. Recent strategic moves & developments
9.5.5. SWOT analysis

9.6. Antibodies Incorporated

9.6.1. Business overview
9.6.2. Financial performance
9.6.3. Product portfolio
9.6.4. Recent strategic moves & developments
9.6.5. SWOT analysis

9.7. EUROIMMUN Medizinische Labordiagnostika AG

9.7.1. Business overview
9.7.2. Financial performance
9.7.3. Product portfolio
9.7.4. Recent strategic moves & developments
9.7.5. SWOT analysis

9.8. Immuno Concepts NA Ltd.,

9.8.1. Business overview
9.8.2. Financial performance
9.8.3. Product portfolio
9.8.4. Recent strategic moves & developments
9.8.5. SWOT analysis

9.9. Inova Diagnostics, Inc.

9.9.1. Business overview
9.9.2. Financial performance
9.9.3. Product portfolio
9.9.4. Recent strategic moves & developments
9.9.5. SWOT analysis

9.10. ZEUS Scientific, Inc 

9.10.1. Business overview
9.10.2. Financial performance
9.10.3. Product portfolio
9.10.4. Recent strategic moves & developments
9.10.5. SWOT analysis

 

Sometimes antibodies recognize their own cells as dangerous and infectious. They fail to recognize self-cells and consider them as a potential threat; therefore they are called as autoantibodies. Autoantibodies turn against their own body and such type of antibodies that attack normal or self-proteins within the nucleus of a cell are termed are antinuclear antibody (ANA). Presence of high percentage of autoantibodies in the body can cause autoimmune diseases and antinuclear antibody test is carried out to detect autoimmune diseases.

A positive test result signifies high ANA content in blood and is reported as both pattern and ratio (known as titer). High level of titer indicates positive result, excessive antinuclear antibodies, and presence of autoimmune disease.

Some of the autoimmune disorders are systemic lupus erythematosus (SLE), Siogren’s syndrome, rheumatoid arthritis, polymyositis, and Hashimoto’s thyroiditis.

Forecast Analysis of the Antinuclear Antibody Testing Market

End-users are demanding antinuclear antibody tests at a high rate due to the rise in cases pertaining to autoimmune diseases. This aspect is predicted to be responsible for the growth of the antinuclear antibody market in the estimated forecast period. Moreover, government’s initiatives to build awareness about medical insurances have pushed numerous people under the safety cover of health policies. This factor is also driving the antinuclear antibody testing market forward in the forecast period. Apart from this, according to AARDA (America Autoimmune Related Diseases Association) around 20% of US population is affected by autoimmune diseases, out of which 75% are women. This factor also pushes the market forward in the U.S.A.

Nevertheless, the growth of the market is hindered due to strict government rules on obtaining antinuclear antibody medical devices. The stringent rules are due to concerns related to the consistency of testing devices. Furthermore, requirement of heavy investments for installing and setting up of testing devices is estimated to restrain the market growth as well. On the brighter side, investments in healthcare facilities and testing kits are projected to create tremendous opportunities in the global antinuclear antibody testing market.

According to the report published by Research Dive, the antinuclear antibody testing market  is anticipated to surpass $2,766.5 million by 2027, from a substantial market size of $1,080.1 million in 2019, with CAGR of 13.0% during the predicted forecast timeframe. The majority of the market size comes from the region of North America as several cases of autoimmune diseases are reported from this area. Some of the significant antinuclear antibody testing market players include Bio-Rad Laboratories, Inc., Erba Diagnostics, Trinity Biotech Plc., Antibodies Incorporated, Thermo Fisher Scientific, EUROIMMUN Medizinische Labordiagnostika AG, Inova Diagnostics, Inc. Immuno Concepts NA Ltd., and ZEUS Scientific, Inc.    

Recent Developments in the Antinuclear Antibody Testing Market

The businesses are going for unique strategies with the help of which they’ll gain a competitive edge in the global market. Some frequently used plans are novel product launches, partnerships and collaborations, investments in research and development, and acquisitions.

In 2019, a systemic lupus erythematosus classification criterion was created by EULAR in partnership with the American college of rheumatology. Here, it was suggested that the immunofluorescence testing on solid-phase ANA screening immunoassay and HEp-2 cells with equal performance is highly preferred.  

In 2018, some unexpected findings were reported from clinical trials to treat SLE (systemic lupus erythematosus). The findings were related to variability in serological testing for ANA (antinuclear antibodies).

Covid-19 Impact on the Market

The Covid-19 pandemic is predicted to impact the antinuclear antibody testing market in a positive way and grow rapidly during the pandemic phase. The primary reason for this rise in market is due to surge in number of people opting for antinuclear antibody tests. These tests confirm the presence of autoimmune disorders in a persons’ body, and hence it is necessary to detect it. Moreover, growing prevalence of autoimmune diseases also leads to the market growth. All these aspects promote the growth of the market during the Covid-19 pandemic period.         

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed